|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Click here to see latest analysisEndo International Plc reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Endo International Plc – Onconova Therapeutics Inc., Ono Pharmaceutical Co., Ltd. Unsponsored ADR, OPKO Health, Inc. and Omeros Corporation (ONTX-US, OPHLY-US, OPK-US and OMER-US) that have also reported […] (Read more...) The post Endo International Plc :ENL-CA: Earnings Analysis: Q1, 2016 By the Numbers : June 16, 2016 appeared first on CapitalCube.
As the information giant looks to focus on financial and legal services, some say it could sell its Intellectual Property & Science unit for 10 times EBITDA, about $3 bills.
“It starts with the customer need,” explained Kumsal Bayazit, Chief Strategy Officer of RELX Group during a recent interview discussing the company’s strategy -- and her role in defining it. “We serve professionals across very different industries, but the needs at the high level are similar. Everybody is looking for